论文部分内容阅读
目的:艾塞那肽是胰高糖素样肽-1受体激动剂,在降糖作用的同时,对血脂等代谢指标也具有潜在的疗效。本试验观察艾塞那肽对初发2型糖尿病患者血糖、体重及血脂谱的治疗效果及血脂的达标率改善情况。方法:对48例初发糖尿病,且体重指数≥24 kg/m~2的患者,给予艾塞那肽治疗12周,观察对患者血糖、非高密度脂蛋白胆固醇(non-HDLC)、低密度脂蛋白胆固醇(LDL-C)、载脂蛋白B、胰岛素抵抗指数(HOMA-IR)及胰岛β细胞功能(HOMA-B)的治疗效果。结果:艾塞那肽治疗12周后,患者血浆糖化血红蛋白水平与基线相比显著降低[(9.81±2.13)vs(6.44±0.83),P<0.01]。此外,与治疗前相比,non-HDLC水平[(4.13±1.31)vs(3.44±0.98),P<0.01]显著下降,低密度脂蛋白胆固醇水平[(3.13±0.92)vs(2.84±0.87),P<0.05]显著下降,载脂蛋白B水平[(0.92±0.26vs(0.86±0.29),P<0.05]显著下降。经艾塞那肽治疗,患者的LDL-C,non-HDLC及TG达标率均有提高,其中non-HDLC(29.2%vs 54.2%,P<0.05)及甘油三酯(33.3%vs 58.3%,P<0.05)在治疗前后达标率存在显著差异。结论:艾塞那肽治疗2型糖尿病除有效控制血糖外,对患者血脂水平也可以发挥一定的调节作用,具有潜在的降低2型糖尿病患者的心血管事件风险。
Aims: Exenatide, a glucagon-like peptide-1 receptor agonist, has a potential therapeutic effect on the metabolic indices such as blood lipids during the hypoglycemic effect. This experiment observed exenatide in patients with newly diagnosed type 2 diabetes blood glucose, body weight and lipid profile of the treatment effect and lipid compliance rate improved. Methods: Forty-eight patients with initial diabetes mellitus and body mass index ≥24 kg / m ~ 2 were treated with exenatide for 12 weeks. The levels of plasma glucose, non-HDLC, Lipoprotein cholesterol (LDL-C), apolipoprotein B, insulin resistance index (HOMA-IR) and pancreatic β-cell function (HOMA-B). RESULTS: After treatment with exenatide for 12 weeks, the plasma glycosylated hemoglobin level was significantly lower than baseline (9.81 ± 2.13 vs 6.44 ± 0.83, P <0.01). In addition, the levels of non-HDLC [(4.13 ± 1.31) vs (3.44 ± 0.98), P <0.01] were significantly lower than those before treatment, and the levels of LDL cholesterol [ , P <0.05], and the levels of apolipoprotein B (0.92 ± 0.26vs (0.86 ± 0.29), P <0.05] decreased significantly.After treatment with exenatide, the levels of LDL- The compliance rates of non-HDLC (29.2% vs 54.2%, P <0.05) and triglycerides (33.3% vs 58.3%, P <0.05) were significantly different before and after treatment.Conclusion: In addition to effective glycemic control, type 2 diabetes mellitus can also modulate lipid levels in patients with type 2 diabetes, potentially reducing the risk of cardiovascular events in patients with type 2 diabetes.